Guide issued for off-label use of antipsychotics
The guide evaluates the use of Abilify, Zyprexa, Seroquel, Risperdal, and Geodon.
A new publication from AHRQ outlines the latest scientific evidence on off-label uses of atypical antipsychotics. The guide evaluates the use of aripiprazole (Abilify, Otsuka), olanzapine (Zyprexa, Lilly), quetiapine (Seroquel, AstraZeneca), risperidone (Risperdal, Janssen), and ziprasidone (Geodon, Pfizer), which are officially approved for treating schizophrenia and bipolar disorder but are often used off-label for conditions such as obsessive-compulsive disorder, dementia-related behavioral disturbances, agitation, anxiety, and psychotic episodes. The guide is the newest publication from the AHRQ Effective Health Care program and can be accessed on-line at
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
